ALK was recognized as a molecular target in NSCLC in 2007, when Dr. Hiroyuki Mano and colleagues reported that 6.7% of Japanese NSCLC patients had a fusion of EML4 with the intracellular kinase domain of ALK. Here, EML4 is linked to non-small cell lung carcinoma.